ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2025
Delayed treatment of severe stroke: room for thrombectomy?
Article in European heart journal supplements : journal of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large vessel occlusion stroke is a significant cause of disability and mortality. Mechanical thrombectomy (MT) has greatly improved outcomes when performed within 6 h of symptom onset. However, many patients present beyond this window, which limits treatment options. Studies show that up to 70% of stroke patients in the USA and 30-40% in Europe arrive after 6 h. Advanced imaging techniques, such as computed tomography perfusion and magnetic resonance imaging, can aid in identifying salvageable tissue (penumbra) and guide late thrombectomy decisions. Trials like DAWN and DEFUSE-3 demonstrated considerable benefits of MT up to 24 h post-stroke in selected patients. Recent research, including the MR CLEAN-LATE, SELECT2, and ANGEL-ASPECT trials, suggests potential advantages for patients with large ischaemic cores (ASPECTS 3-5) without the need for advanced imaging. Despite these advancements, challenges persist, such as identifying optimal candidates, reducing haemorrhagic risks, and managing complications like no-reflow phenomena. Future research aims to enhance patient selection, optimize treatment strategies, and investigate new pharmacological approaches. Endovascular therapy continues to progress, providing new treatment options for late-presenting stroke patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.